IXHL · Incannex Healthcare Limited

Summary

Incannex Healthcare issued a press release supporting a White House Executive Order accelerating psychedelic treatments, highlighting alignment of its PSX-001 program for Generalized Anxiety Disorder with the improved regulatory environment.

Key takeaways

• PSX-001 oral synthetic psilocybin Phase 2 trial showed 12.8-point HAM-A reduction vs 3.6 placebo (p<0.0001).
• PSX-001 achieved 44% clinically meaningful response rate, four times placebo, and 27% remission rate sustained through 11 weeks.
• No serious adverse events or discontinuations in 73-patient Phase 2 trial completed in 2025.
• Company holds over $70 million cash, no debt, with active U.S. IND for PSX-001.
• Executive Order directs FDA to prioritize psychedelics with Breakthrough Therapy status and create Right to Try pathways.
• CEO states order reduces regulatory risk for psilocybin class, advancing PSX-001 urgently.